Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
Media Release Copenhagen, Denmark, June 6, 2022Â Interim results of tisotumab vedotin plus pembrolizumab from…
Checkmarx Joins the Claude Marketplace
Getting Value From AI Takes More Than Buying The Tools